Sign Up Today and Learn More About Garuda Therapeutics Stock
Invest in or calculate the value of your shares in Garuda Therapeutics or other pre-IPO companies through EquityZen's platform.
Garuda Therapeutics Stock (GATH)
Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases.
About Garuda Therapeutics Stock
Founded
2021
Headquarters
Cambridge, MA, US
Industries
Science and Engineering, Health Care, Biotechnology
Garuda Therapeutics Press Mentions
Stay in the know about the latest news on Garuda Therapeutics
Pluripotent stem cell-derived hematopoietic lineages
patents • Apr 02, 2025
Stem Cell Therapy Market Global Forecast 2025-2030: Breakthroughs in Gene Editing & Cell Therapy Propel Stem Cell Market Expansion to 2030
globenewswire • Mar 18, 2025
Shift Bioscience Announces Key Appointments to Advance Rejuvenation Therapeutics Pipeline
businesswire • Mar 12, 2025
citybiz+ Garuda Therapeutics Raises $50 Million, Names New CEO to Push Stem Cell Therapies
citybiz • Mar 07, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing
finsmes • Mar 05, 2025
Garuda Therapeutics Management
Leadership team at Garuda Therapeutics
Founder, President, and Chief Executive Officer
Dhvanit Shah
Chief Technology Officer
David Digiusto
Join now and verify your accreditation status to gain access to:
- Garuda Therapeutics Current Valuation
- Garuda Therapeutics Stock Price
- Garuda Therapeutics Management
- Available deals in Garuda Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Garuda Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Garuda Therapeutics Revenue and Financials
- Garuda Therapeutics Highlights
- Garuda Therapeutics Business Model
- Garuda Therapeutics Risk Factors
- Garuda Therapeutics Research Report from SACRA Research
Trading Garuda Therapeutics Stock
How to invest in Garuda Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Garuda Therapeutics through EquityZen funds. These investments are made available by existing Garuda Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Garuda Therapeutics stock?
Shareholders can sell their Garuda Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
